LLR Care Homes Diabetes Care Plan and Good Practice Guide(2 MB)
Date added: 7th Oct 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| BECLOMETASONE Inhaler - CFC free (UPDATED) | Green | Asthma |
QVAR® brand recommended for adults. Soprobec® brand recommended only for children. Clenil Modulite® inhalers are being discontinued. Patients prescribed Clenil Modulite® 50 microgram or 100 microgram inhalers should be switched to the equivalent strength of Soprobec®, in line with the local SBAR and Medicines Supply Notification (MSN)
Soprobec® provides a like-for-like dose of beclometasone dipropionate; however, it does not include a dose counter.
|
| DEXAMFETAMINE (UPDATED) | Orange | Excessive sleepiness caused by narcolepsy | |
| EMICIZUMAB (Hemlibra®) (NEW) | Red | For acquired haemophilia |
As per BSCH guidelines. Agreement to fund locally whilst NHSE review commission policy |
| EPOETIN ZETA (Retacrit®) (NEW) | Red | Anaemia | |
| ESOMEPRAZOLE GASTRO-RESISTANT GRANULES SACHETS (NEW) | Yellow | For paediatric patients with enteral feeding tubes |
Use limited until the current shortage of lansoprazole orodispersible tablets has resolved. |
| FAMPRIDINE PROLONGED RELEASE (Fampyra®) (UPDATED) | Red | Multiple sclerosis and associated walking impairment | |
| FINERENONE (Kerendia®) | Yellow | Treatment of Chronic Kidney Disease (Stage 3 and 4 with albuminuria) associated with Type 2 Diabetes in Adults |
In line with NICE TA877 Use in line with the CKD pathway |
| FINERENONE (Kerendia®) (NEW) | Red | Chronic heart failure with preserved or mildly reduced ejection fraction |
In line with NICE TA1182 Funding from: 3rd November 2026 |
| FOSCARNET INTRAVITREAL (NEW) | Red | for viral retinitis |
Intravitreal injection Requires micro code |
| GANCICLOVIR 0.15% EYE GEL (Virgan®) | Green | Acute herpetic keratitis | |
| GANCICLOVIR INTRAVITREAL (NEW) | Red | for viral retinitis |
Intravitreal injection Requires micro code |
| LANREOTIDE (NEW) | Red | Monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease | |
| LIRAGLUTIDE (Diavic®) (UPDATED) | Green | Type 2 diabetes |
Diavic® is the preferred liraglutide formulation across LLR. Available only in line with NICE NG28 |
| MICONAZOLE ORAL GEL (NEW) | Green | Oral candidiasis in adults and children aged 4 months and over |
Nystatin should be used for oral candidiasis in infants under 4 months of age, as licensed. |
| NYSTATIN 100,000 UNIT/ML ORAL SUSPENSION (NEW) | Green | Oral candidiasis in infants aged under 4 months | |
| TICAGRELOR (NEW) | Red | For ischaemic stroke or TIA in patients known or suspected of being poor CYP2C19 metabolisers |
Alternative to clopidogrel for secondary prevention in patients confirmed or suspected to be poor CYP2C19 metabolisers. |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter – August & September 2026(433 KB)
Date added: 30th Sep 2026
Respiratory Prescribing Group Minutes July 2026(135 KB)
Date added: 28th Sep 2026
TAS Minutes 23rd June 2026(360 KB) - LMSG/LLR APC minutes
Date added: 23rd Sep 2026
TAS Minutes 25th August 2026(340 KB) - LMSG/LLR APC minutes
Date added: 23rd Sep 2026
LLR APC Meeting Minutes August 2026(388 KB) - LMSG/LLR APC minutes
Date added: 15th Sep 2026
SBAR LLR ICB Recommendations Clenil Discontinuation(615 KB)
Date added: 15th Sep 2026
LLR Lipid Pathway(715 KB) - Guidelines
Date added: 12th Oct 2022
Antipsychotic Prescribing Guide for Primary Care(531 KB) - Guidelines
Date added: 29th Jul 2022
Infant Formula Prescribing Guidance(844 KB) - Guidelines
Date added: 14th Nov 2017
Management of Wheeze in Children Under 5 Years(506 KB) - Guidelines
Date added: 4th May 2016
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more